DE60136562D1 - Heteroaryl-harnstoff-neuropeptid-y-y5-rezeptor-antagonisten - Google Patents

Heteroaryl-harnstoff-neuropeptid-y-y5-rezeptor-antagonisten

Info

Publication number: DE60136562D1
Authority: DE; Germany
Prior art keywords: heteroaryl; receptor antagonists; neuropeptide; urea; urea neuropeptide
Prior art date: 2000-12-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60136562T

Other languages

English (en)

Inventor

Andrew W Stamford

Youhao Dong

Combie Stuart W Mc

Yusheng Wu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Sharp and Dohme Corp

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-21

Filing date

2001-12-17

Publication date

2008-12-24

2001-12-17 Application filed by Schering Corp filed Critical Schering Corp

2008-12-24 Application granted granted Critical

2008-12-24 Publication of DE60136562D1 publication Critical patent/DE60136562D1/de

2021-12-18 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

101710151321 Melanostatin Proteins 0.000 title 1
102400000064 Neuropeptide Y Human genes 0.000 title 1
102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 title 1
101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 title 1
239000004202 carbamide Substances 0.000 title 1
URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

DE60136562T 2000-12-21 2001-12-17 Heteroaryl-harnstoff-neuropeptid-y-y5-rezeptor-antagonisten Expired - Lifetime DE60136562D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US25730800P	2000-12-21	2000-12-21
PCT/US2001/049302 WO2002049648A1 (en)	2000-12-21	2001-12-17	Heteroaryl urea neuropeptide y y5 receptor antagonists

Publications (1)

Publication Number	Publication Date
DE60136562D1 true DE60136562D1 (de)	2008-12-24

Family

ID=22975741

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60136562T Expired - Lifetime DE60136562D1 (de)	2000-12-21	2001-12-17	Heteroaryl-harnstoff-neuropeptid-y-y5-rezeptor-antagonisten

Country Status (22)

Country	Link
US (1)	US6982267B2 (de)
EP (1)	EP1343503B1 (de)
JP (1)	JP4226326B2 (de)
KR (1)	KR20030061458A (de)
CN (2)	CN1807426A (de)
AR (1)	AR035520A1 (de)
AT (1)	ATE413880T1 (de)
AU (2)	AU2002234056B2 (de)
BR (1)	BR0116379A (de)
CA (1)	CA2432809C (de)
DE (1)	DE60136562D1 (de)
ES (1)	ES2316486T3 (de)
HK (1)	HK1054333A1 (de)
HU (1)	HUP0303339A3 (de)
IL (1)	IL156157A0 (de)
MX (1)	MXPA03005745A (de)
NO (1)	NO20032861L (de)
NZ (1)	NZ526174A (de)
PE (1)	PE20020761A1 (de)
SG (1)	SG138463A1 (de)
WO (1)	WO2002049648A1 (de)
ZA (1)	ZA200304348B (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6946476B2 (en) *	2000-12-21	2005-09-20	Schering Corporation	Heteroaryl urea neuropeptide Y Y5 receptor antagonists
AU2002327534A1 (en) *	2001-08-17	2003-03-03	Merck And Co., Inc.	Tyrosine kinase inhibitors
EP1430027B1 (de) *	2001-09-14	2010-09-01	High Point Pharmaceuticals, LLC	Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative
US6673829B2 (en)	2001-09-14	2004-01-06	Novo Nordisk A/S	Aminoazetidine,-pyrrolidine and -piperidine derivatives
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
CN1678608A (zh) *	2002-07-02	2005-10-05	先灵公司	新的神经肽yy5受体拮抗剂
MXPA05004115A (es) *	2002-10-18	2005-06-22	Pfizer Prod Inc	Ligandos del receptor cannabionoide y usos de los mismos.
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
CA2551037A1 (en)	2003-09-22	2005-03-31	Banyu Pharmaceutical Co., Ltd.	Novel piperidine derivative
US20070099938A1 (en) *	2003-10-24	2007-05-03	Ono Pharmaceutical Co., Ltd.	Antistress drug and medical use thereof
US7291744B2 (en)	2003-11-13	2007-11-06	Bristol-Myers Squibb Company	N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
TW200630337A (en)	2004-10-14	2006-09-01	Euro Celtique Sa	Piperidinyl compounds and the use thereof
JP4926069B2 (ja)	2004-11-01	2012-05-09	アミリン・ファーマシューティカルズ，インコーポレイテッド	肥満ならびに肥満関連疾患および障害の治療方法
AU2005311930B9 (en)	2004-12-03	2009-09-10	Merck Sharp & Dohme Corp.	Substituted piperazines as CB1 antagonists
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
US8138206B2 (en)	2005-05-30	2012-03-20	Msd. K.K.	Piperidine derivative
WO2007018248A1 (ja)	2005-08-10	2007-02-15	Banyu Pharmaceutical Co., Ltd.	ピリドン化合物
BRPI0614649A2 (pt)	2005-08-11	2011-04-12	Amylin Pharmaceuticals Inc	polipeptìdeos hìbridos com propriedades selecionáveis
AU2006279680B2 (en)	2005-08-11	2012-12-06	Amylin Pharmaceuticals, Llc	Hybrid polypeptides with selectable properties
DE602006017712D1 (de)	2005-08-24	2010-12-02	Banyu Pharma Co Ltd	Phenylpyridonderivat
JPWO2007029847A1 (ja)	2005-09-07	2009-03-19	萬有製薬株式会社	二環性芳香族置換ピリドン誘導体
WO2007041052A2 (en)	2005-09-29	2007-04-12	Merck & Co., Inc.	Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
KR20080059233A (ko)	2005-10-21	2008-06-26	노파르티스 아게	레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물
EP1944301A4 (de)	2005-10-27	2012-01-04	Msd Kk	Neue benzoxathiinderivate
ES2381205T3 (es)	2005-11-10	2012-05-24	Msd K.K.	Derivado espiro aza-sustituido
RU2008133381A (ru)	2006-01-18	2010-02-27	Шеринг Корпорейшн (US)	Модуляторы каннабиноидного рецептора
WO2007110449A1 (en)	2006-03-29	2007-10-04	Euro-Celtique S.A.	Benzenesulfonamide compounds and their use
US8937181B2 (en)	2006-04-13	2015-01-20	Purdue Pharma L.P.	Benzenesulfonamide compounds and the use thereof
TW200815353A (en)	2006-04-13	2008-04-01	Euro Celtique Sa	Benzenesulfonamide compounds and their use
WO2008026564A1 (fr)	2006-08-30	2008-03-06	Shionogi & Co., Ltd.	Dérivés d'urée
EP2059516A1 (de) *	2006-08-30	2009-05-20	BIOVITRUM AB (publ)	Pyridinverbindungen zur behandlung von mit gpr119 in zusammenhang stehenden erkrankungen
EP2698157B1 (de)	2006-09-22	2015-05-20	Merck Sharp & Dohme Corp.	Verfahren zur Behandlung von Fettsäure-Synthese-Hemmern
AU2007301126A1 (en)	2006-09-28	2008-04-03	Banyu Pharmaceutical Co., Ltd.	Diaryl ketimine derivative
KR20090097184A (ko)	2006-12-06	2009-09-15	스미스클라인 비참 코포레이션	비시클릭 화합물 및 항당뇨병제로서의 용도
AU2008233662B2 (en)	2007-04-02	2012-08-23	Msd K.K.	Indoledione derivative
WO2008124118A1 (en) *	2007-04-09	2008-10-16	Purdue Pharma L.P.	Benzenesulfonyl compounds and the use therof
US20100197564A1 (en) *	2007-04-19	2010-08-05	Schering Corporation	Diaryl morpholines as cb1 modulators
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en)	2007-06-04	2020-10-20	Kunwar Shailubhai	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2694264A1 (en) *	2007-06-28	2009-01-08	Intervet International B.V.	Substituted piperazines as cb1 antagonists
EP2170846A2 (de) *	2007-06-28	2010-04-07	Intervet International BV	Substituierte piperazine als cb1-antagonisten
US8765736B2 (en)	2007-09-28	2014-07-01	Purdue Pharma L.P.	Benzenesulfonamide compounds and the use thereof
EP2264026A4 (de)	2008-03-06	2012-03-28	Msd Kk	Alkylaminopyridinderivate
JPWO2009119726A1 (ja)	2008-03-28	2011-07-28	Ｍｓｄ株式会社	メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
EP2146210A1 (de)	2008-04-07	2010-01-20	Arena Pharmaceuticals, Inc.	Verfahren zur Verwendung eines AG-Protein-gekoppelten Rezeptors zur Identifikation von Peptid-YY (PPY)-Sekretagogen sowie Verbindungen zur Behandlung durch PYY modulierter Leiden
CA2726917C (en)	2008-06-04	2018-06-26	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009261248A1 (en)	2008-06-19	2009-12-23	Banyu Pharmaceutical Co., Ltd.	Spirodiamine-diarylketoxime derivative
JP2011528375A (ja)	2008-07-16	2011-11-17	シナジーファーマシューティカルズインコーポレイテッド	胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US20110124674A1 (en)	2008-07-30	2011-05-26	Hiroyuki Kishino	5/5-or 5/6-membered condensed ring cycloalkylamine derivative
MX2011004258A (es)	2008-10-22	2011-06-01	Merck Sharp & Dohme	Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
JP5635991B2 (ja)	2008-10-30	2014-12-03	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	イソニコチンアミドオレキシン受容体アンタゴニスト
JP5557845B2 (ja)	2008-10-31	2014-07-23	メルク・シャープ・アンド・ドーム・コーポレーション	糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
US20110243940A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Bicyclic pyranone derivatives and methods of use thereof
EP2379547A1 (de)	2008-12-16	2011-10-26	Schering Corporation	Pyridopyrimidinderivate und verfahren zu deren anwendung
AU2011218830B2 (en)	2010-02-25	2014-07-24	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
EP3243385B1 (de)	2011-02-25	2021-01-13	Merck Sharp & Dohme Corp.	Neue cyclische azabenzimidazolderivate als antidiabetika
CN102718703B (zh) *	2011-03-31	2016-09-14	中国医学科学院药物研究所	Gk和ppar双重激动活性的含有二甲基的芳基脲类衍生物
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
AU2013296470B2 (en)	2012-08-02	2016-03-17	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
CN103910694B (zh) *	2012-12-29	2016-08-24	广东东阳光药业有限公司	一种2-芳基腈噻唑衍生物的制备方法
EP2958562A4 (de)	2013-02-22	2016-08-10	Merck Sharp & Dohme	Antidiabetische bicyclische verbindungen
US9650375B2 (en)	2013-03-14	2017-05-16	Merck Sharp & Dohme Corp.	Indole derivatives useful as anti-diabetic agents
CA2905435A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (de)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Agonisten der guanylatcyclase und deren verwendungen
CN105764916B (zh)	2013-06-05	2021-05-18	博士医疗爱尔兰有限公司	鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
MX2017002610A (es)	2014-08-29	2017-10-11	Tes Pharma S R L	INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
WO2017114377A1 (zh) *	2015-12-29	2017-07-06	四川海思科制药有限公司	一种苯基杂环衍生物及其在医药上的用途
AR109950A1 (es)	2016-10-14	2019-02-06	Tes Pharma S R L	INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
EP3551176A4 (de)	2016-12-06	2020-06-24	Merck Sharp & Dohme Corp.	Antidiabetische heterocyclische verbindungen
US10968232B2 (en)	2016-12-20	2021-04-06	Merck Sharp & Dohme Corp.	Antidiabetic spirochroman compounds
WO2019222267A1 (en) *	2018-05-15	2019-11-21	The Scripps Research Institute	Abhd12 inhibitors and methods of making and using same
TW202033516A (zh)	2018-11-20	2020-09-16	義大利商Ｔｅｓ製藥（股份）責任有限公司	α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑
WO2020167706A1 (en)	2019-02-13	2020-08-20	Merck Sharp & Dohme Corp.	5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (de)	2019-08-08	2024-02-28	Merck Sharp & Dohme LLC	Heteroaryl-pyrrolidin- und piperidinorexinrezeptor-agonisten
EP4200295A1 (de)	2020-08-18	2023-06-28	Merck Sharp & Dohme LLC	Bicycloheptanpyrrolidinorexinrezeptoragonisten

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2928485A1 (de) *	1979-07-14	1981-01-29	Bayer Ag	Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US4623662A (en)	1985-05-23	1986-11-18	American Cyanamid Company	Antiatherosclerotic ureas and thioureas
US5602024A (en)	1994-12-02	1997-02-11	Synaptic Pharmaceutical Corporation	DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
CA2273102A1 (en) *	1996-12-03	1998-06-11	Banyu Pharmaceutical Co., Ltd.	Urea derivatives
AR016817A1 (es) *	1997-08-14	2001-08-01	Smithkline Beecham Plc	Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
EP1041982B1 (de) *	1997-12-22	2011-10-19	Bayer HealthCare LLC	HEMMUNG DER p38 KINASE AKTIVITÄT DURCH SUBSTITUIERTE HETEROCYCLISCHE HARNSTOFFE
CA2350714A1 (en)	1998-11-10	2000-05-18	Merck & Co., Inc.	Spiro-indolines as y5 receptor antagonists
EP1184373A4 (de) *	1999-04-20	2004-10-20	Meiji Seika Kaisha	Tricyclische verbindungen
TWI279402B (en)	1999-08-20	2007-04-21	Banyu Pharma Co Ltd	Spiro compounds having NPY antagonistic activities and agents containing the same
ATE466573T1 (de)	1999-11-26	2010-05-15	Shionogi & Co	Npyy5-antagonisten

2001
- 2001-12-17 IL IL15615701A patent/IL156157A0/xx unknown
- 2001-12-17 WO PCT/US2001/049302 patent/WO2002049648A1/en active IP Right Grant
- 2001-12-17 NZ NZ526174A patent/NZ526174A/xx unknown
- 2001-12-17 ES ES01985069T patent/ES2316486T3/es not_active Expired - Lifetime
- 2001-12-17 CN CNA2006100050504A patent/CN1807426A/zh active Pending
- 2001-12-17 AU AU2002234056A patent/AU2002234056B2/en not_active Ceased
- 2001-12-17 CA CA2432809A patent/CA2432809C/en not_active Expired - Fee Related
- 2001-12-17 AU AU3405602A patent/AU3405602A/xx active Pending
- 2001-12-17 HU HU0303339A patent/HUP0303339A3/hu unknown
- 2001-12-17 AT AT01985069T patent/ATE413880T1/de not_active IP Right Cessation
- 2001-12-17 MX MXPA03005745A patent/MXPA03005745A/es active IP Right Grant
- 2001-12-17 KR KR10-2003-7008229A patent/KR20030061458A/ko not_active Application Discontinuation
- 2001-12-17 EP EP01985069A patent/EP1343503B1/de not_active Expired - Lifetime
- 2001-12-17 DE DE60136562T patent/DE60136562D1/de not_active Expired - Lifetime
- 2001-12-17 BR BR0116379-5A patent/BR0116379A/pt not_active Application Discontinuation
- 2001-12-17 CN CNA018211720A patent/CN1482912A/zh active Pending
- 2001-12-17 JP JP2002550988A patent/JP4226326B2/ja not_active Expired - Fee Related
- 2001-12-17 SG SG200503925-0A patent/SG138463A1/en unknown
- 2001-12-17 AR ARP010105841A patent/AR035520A1/es not_active Application Discontinuation
- 2001-12-18 US US10/026,651 patent/US6982267B2/en not_active Expired - Lifetime
- 2001-12-18 PE PE2001001267A patent/PE20020761A1/es not_active Application Discontinuation
2003
- 2003-06-03 ZA ZA200304348A patent/ZA200304348B/en unknown
- 2003-06-20 NO NO20032861A patent/NO20032861L/no unknown
- 2003-09-19 HK HK03106723.8A patent/HK1054333A1/zh unknown

Also Published As

Publication number	Publication date
AR035520A1 (es)	2004-06-02
CN1482912A (zh)	2004-03-17
EP1343503A4 (de)	2004-03-17
NO20032861D0 (no)	2003-06-20
CA2432809C (en)	2010-11-30
CA2432809A1 (en)	2002-06-27
US6982267B2 (en)	2006-01-03
ATE413880T1 (de)	2008-11-15
NZ526174A (en)	2004-12-24
EP1343503A1 (de)	2003-09-17
HUP0303339A3 (en)	2004-04-28
CN1807426A (zh)	2006-07-26
EP1343503B1 (de)	2008-11-12
HUP0303339A2 (hu)	2004-01-28
NO20032861L (no)	2003-08-21
ZA200304348B (en)	2004-09-09
IL156157A0 (en)	2003-12-23
JP2004516267A (ja)	2004-06-03
HK1054333A1 (zh)	2003-11-28
BR0116379A (pt)	2003-09-30
MXPA03005745A (es)	2003-09-05
JP4226326B2 (ja)	2009-02-18
KR20030061458A (ko)	2003-07-18
AU3405602A (en)	2002-07-01
SG138463A1 (en)	2008-01-28
ES2316486T3 (es)	2009-04-16
PE20020761A1 (es)	2002-08-22
US20030055062A1 (en)	2003-03-20
AU2002234056B2 (en)	2005-04-07
WO2002049648A1 (en)	2002-06-27

Legal Events

Date	Code	Title	Description
2009-11-26	8364	No opposition during term of opposition

Publication	Publication Date	Title
DE60136562D1 (de)	2008-12-24	Heteroaryl-harnstoff-neuropeptid-y-y5-rezeptor-antagonisten
ATE232200T1 (de)	2003-02-15	Neuropeptid y5-rezeptorantagonisten
HK1054547A1 (zh)	2003-12-05	取代的脲神經肽yy5受體拮抗劑
NO20022835D0 (no)	2002-06-14	Substituerte imidazolneuropeptid Y Y5-reseptorantagonister
ATE368659T1 (de)	2007-08-15	Thrombinrezeptorantagonisten
IL159643A0 (en)	2004-06-01	Substituted urea neuropeptide y y5 receptor antagonists
ATE400558T1 (de)	2008-07-15	Metabotropische glutamatrezeptor-antagonisten
ATE439344T1 (de)	2009-08-15	Muscarin-antagonisten
NO20025754L (no)	2002-11-29	IL-8 Reseptor-antagonister
AU2003251739A8 (en)	2004-01-23	New neuropeptide y y5 receptor antagonists
DE60112051D1 (de)	2005-08-25	Il-8 rezeptor antagonisten
DE60126480D1 (de)	2007-03-22	Il-8 rezeptor-antagonisten
DE60130000D1 (de)	2007-09-27	Zwitterionische tachykinin-rezeptor-antagonisten
MA25739A1 (fr)	2003-04-01	Antagonistes recepteurs il-8
MA25659A1 (fr)	2002-12-31	Antagonistes recepteurs il-8
NO20021113D0 (no)	2002-03-06	Vitronectin-reseptor-antagonister
NO20024366D0 (no)	2002-09-12	IL-8 reseptorantagonister
SE0003996D0 (sv)	2000-11-01	Receptorantagonister
NO20040339L (no)	2004-01-26	Nye neuropeptid Y Y5-reseptorantagonister.
DK1218005T3 (da)	2005-04-11	Vitronectinreptorantagonister